PHS
CLDX icon

PFM Health Sciences’s Celldex Therapeutics CLDX Stock Holding History

PFM Health Sciences’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8M Buy
342,751
+17,794
+5% +$575K 1.09% 33
2026
Q1 		$10.3M Buy
324,957
+191,796
+144% +$5.23M 0.94% 37
2025
Q4 		$3.62M Buy
+133,161
New +$3.51M 0.36% 61
2024
Q4 		– Sell
-52,120
Closed -$1.77M – 90
2024
Q3 		$1.77M Hold
52,120
– – 0.1% 70
2024
Q2 		$1.93M Buy
52,120
+17,120
+49% +$646K 0.1% 70
2024
Q1 		$1.47M Hold
35,000
– – 0.07% 84
2023
Q4 		$1.39M Buy
+35,000
New +$1.03M 0.08% 63

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PFM Health Sciences's CLDX Position: Q2 2026 in Review

PFM Health Sciences increased its Celldex Therapeutics (CLDX) stake by 5.5% in Q2 2026, buying an estimated $575K and bringing the position to 342,751 shares worth $12.8M. The position accounts for 1.09% of the portfolio, ranked #33.

PFM Health Sciences first reported a position in CLDX in Q4 2023 and has held it in 7 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • PFM Health Sciences held 342,751 shares of Celldex Therapeutics worth $12.8M as of Q2 2026.
  • PFM Health Sciences bought 17,794 Celldex Therapeutics shares in Q2 2026, an estimated $575K.
  • Celldex Therapeutics made up 1.09% of PFM Health Sciences's portfolio in Q2 2026, its #33 holding.
  • PFM Health Sciences first reported a position in Celldex Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.